SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 180.17 |
Enterprise Value ($M) | 173.18 |
Book Value ($M) | 6.70 |
Book Value / Share | 0.52 |
Price / Book | 26.89 |
NCAV ($M) | 6.70 |
NCAV / Share | 0.52 |
Price / NCAV | 26.91 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -1.33 |
Return on Assets (ROA) | -0.75 |
Return on Equity (ROE) | -0.76 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 23.74 |
Current Ratio | 23.74 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 6.99 |
Assets | 6.99 |
Liabilities | 0.29 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | -9.33 |
Net Income | -8.89 |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -6.48 |
Cash from Investing | 0.00 |
Cash from Financing | 0.00 |
(click for more detail) |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
9,394 | 34,464 | 27.26 | |
5,690 | 5,900 | 96.44 | |
17,084 | 11,118 | 153.66 | |
1,732 | 5,605 | 30.90 | |
3,176 | 6,343 | 50.07 | |
(click for more detail) |
Similar Companies | |
---|---|
GDTC – CytoMed Therapeutics Limited | GHSI – Guardion Health Sciences, Inc. |
GLMD – Galmed Pharmaceuticals Ltd. | GLTO – Galecto, Inc. |
GNLX – Genelux Corporation |
Financial data and stock pages provided by
Fintel.io